Related Experiment Videos
Do infants with stage IV-S neuroblastoma need treatment?
Insights
Stage IV-S neuroblastoma in infants often shows spontaneous regression, with most patients benefiting from minimal intervention. This study highlights a high 2-year survival rate of 87% for neuroblastoma patients with this specific disease pattern.
Area of Science:
- Pediatric Oncology
- Cancer Research
- Clinical Medicine
Background:
- Stage IV-S neuroblastoma is a unique pediatric cancer subtype.
- Characterized by small primary tumors and widespread metastasis to liver, skin, and marrow.
- Often presents in infants under 12 months of age.
Purpose of the Study:
- To report treatment outcomes for infants with stage IV-S neuroblastoma diagnosed between 1976 and 1979.
- To evaluate the efficacy of various treatment modalities in this specific patient cohort.
- To assess the long-term survival and disease progression in stage IV-S neuroblastoma.
Main Methods:
- Retrospective analysis of 31 infants diagnosed with stage IV-S neuroblastoma.
- Review of treatment interventions including primary tumor resection, liver irradiation, and chemotherapy.
- Assessment of disease regression, complications, and survival rates.
Main Results:
- A projected 2-year survival rate of 87% was observed.
- Spontaneous regression of disease occurred in 16 patients.
- Nine patients treated solely with primary tumor resection survived.
- Four patients died within the first two months due to complications.
Conclusions:
- Infants with stage IV-S neuroblastoma generally have a favorable prognosis with minimal treatment.
- Early complications are the primary risk factor for mortality.
- Late disease progression is uncommon in this neuroblastoma subtype.
Abstract:
The study reports the results of treatment in 31 infants under age 12 months with stage IV-S neuroblastoma diagnosed between 1976 and 1979. All had small or undetected primary tumours associated with disease in one or more of the following sites: liver, skin, or marrow. The primary site was left adrenal (in 16), and other areas included paravertebral, mediastinum, and pelvis (in 5); in 3 the primary site could not be found. Distant disease was found in the liver (in 29), marrow (in 16), and skin (in 8). Other sites affected were pancreas, pleura, peritoneum, and regional nodes. Treatment varied according to the clinical course of the disease; most patients had very little. In 19 primary tumour was resected, in 21 the liver was irradiated with a median dose of 450 rad, and 15 received chemotherapy in courses varying between 1 month and 1 year. Nine patients had resection of the primary tumour as their only treatment and all survive; a total of 16 patients had sites of disease which regressed spontaneously. Four of 31 patients died in the first 2 months despite vigorous measures, all from some complication of the disease or its treatment. The projected 2-year survival rate is 87%. Children with this 'special' pattern of widespread neuroblastoma fare well with little or no treatment unless early complications develop. In this study none died of late progression of their disease.